类风湿关节炎合并新诊断早期结直肠癌、肺癌或前列腺癌患者接受肿瘤坏死因子抑制剂治疗的生存分析:回顾性队列研究
该回顾性队列研究基于监测、流行病学和最终结果(SEER)数据库关联的Medicare数据,纳入2008年1月1日至2019年12月31日期间诊断为早期(局限或区域)结直肠癌(n=514)、肺癌(n=864)或前列腺癌(n=603)的66岁及以上类风湿关节炎患者,比较诊断后3年内使用肿瘤坏死因子(TNF)抑制剂、传统合成改善病情抗风湿药(csDMARDs)或无DMARDs者的5年总生存和癌症特异性生存。在1、2、3年标志点分析中,任何癌症均未观察到TNF抑制剂与更差生存的显著有害关联;第1年总生存的比较中,TNF抑制剂 vs csDMARDs的风险比(HR)在结直肠癌为0.72(0.43-1.21),肺癌为0.70(0.49-1.00),前列腺癌为0.80(0.44-1.44)。
要点
- 在早期结直肠癌、肺癌或前列腺癌诊断后3年内使用TNF抑制剂,与csDMARDs或无DMARDs相比,未观察到与更差生存显著有害关联。
- 第1年总生存的HR(TNF抑制剂 vs csDMARDs):结直肠癌0.72(0.43-1.21),肺癌0.70(0.49-1.00),前列腺癌0.80(0.44-1.44)。
- 三个癌症队列中,第一年内使用糖皮质激素者的总生存和癌症特异性生存均显著更差。
核心结论
- 在结直肠癌、肺癌或前列腺癌诊断后3年内接受TNF抑制剂治疗,与接受csDMARDs或未接受任何DMARDs者相比,未观察到与更差生存显著有害关联。
- 这些发现可能不适用于其他人群或其他癌症类型。
研究设计与样本
- 回顾性队列研究,对监测、流行病学和最终结果(SEER)数据库关联的Medicare数据集进行二次数据分析。
- 纳入2008年1月1日至2019年12月31日期间诊断为早期(局限或区域)结直肠癌(n=514)、肺癌(n=864)或前列腺癌(n=603)的66岁及以上类风湿关节炎患者。
- 仅纳入癌症诊断后第一年内接受TNF抑制剂、csDMARDs或无DMARDs的患者;暴露为癌症诊断后3年内使用TNF抑制剂、csDMARDs或无DMARDs。
- 主要结局为5年总生存和癌症特异性生存;在第1、2、3年进行标志点分析,采用倾向评分调整的Cox回归。
- 有类风湿关节炎和癌症亲身经历者未参与本研究的设计或实施。
主要发现
- 结直肠癌队列平均年龄76.1岁(SD 6.4),女性385/514(75%),男性129/514(25%),白人和非西班牙裔405/514(79%)。
- 肺癌队列平均年龄74.8岁(SD 5.9),女性632/864(73%),男性232/864(27%),白人和非西班牙裔743/864(86%)。
- 前列腺癌队列平均年龄73.1岁(SD 5.1),男性603/603(100%),白人和非西班牙裔492/603(82%)。
- 癌症诊断后第一年内任何时间接受TNF抑制剂(伴或不伴csDMARDs)者:结直肠癌80/514(16%),肺癌102/864(12%),前列腺癌120/603(20%)。
- 三个癌症在三个标志点分析中,总生存或癌症特异性生存均未观察到显著有害关联;第1年总生存的HR(TNF抑制剂 vs csDMARDs):结直肠癌0.72(0.43-1.21),肺癌0.70(0.49-1.00),前列腺癌0.80(0.44-1.44)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些发现可能不适用于其他人群或其他癌症类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor necrosis factor (TNF) inhibitors could impair tumoural immunity in patients with rheumatoid arthritis and cancer. We aimed to investigate the association between survival and TNF inhibitor treatment during the first 3 years after a diagnosis of colorectal, lung, or prostate cancer in patients with rheumatoid arthritis. METHODS: In this cohort study, we conducted a secondary data analysis of the Surveillance, Epidemiology, and End Results Medicare-linked dataset. We included patients aged 66 years and older with rheumatoid arthritis diagnosed with colorectal, lung, or prostate cancer between Jan 1, 2008, and Dec 31, 2019, using ICD-O-3 site and histology codes. We limited the cohort to patients who had early-stage cancer (localised or regional). We only included patients who received TNF inhibitors, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), or no DMARDs in the first year after cancer diagnosis. The primary outcomes were 5-year overall survival and cancer-specific survival. Exposures were use of TNF inhibitors, conventional synthetic DMARDs, or no DMARDs within 3 years after cancer diagnosis. Other covariates included demographics and comorbidities. We conducted landmark analyses at years 1, 2, and 3, with Cox regression adjusted by propensity scores. People with lived experience of rheumatoid arthritis and cancer were not involved in the design or conduct of this study. FINDINGS: We identified three cohorts of patients diagnosed with early-stage colorectal cancer (n=514), lung cancer (n=864), or prostate cancer (n=603) between Jan 1, 2008, and Dec 31, 2019. In the colorectal cancer cohort, the mean age was 76·1 years (SD 6·4), 385 (75%) of 514 patients were female, 129 (25%) were male, and 405 (79%) were White and non-Hispanic. In the lung cancer cohort, the mean age was 74·8 years (SD 5·9), 632 (73%) of 864 patients were female, 232 (27%) were male, and 743 (86%) were White and non-Hispanic. In the prostate cancer cohort, the mean age was 73·1 years (SD 5·1), 603 (100%) patients were male, and 492 (82%) were White and non-Hispanic. 80 (16%) of 514 patients with colorectal cancer, 102 (12%) of 864 patients with lung cancer, and 120 (20%) of 603 patients with prostate cancer received TNF inhibitors with or without conventional synthetic DMARDs at any time during the first year after cancer diagnosis. No significant deleterious association was observed for overall survival or cancer-specific survival for any of the cancers at any of the three landmark points. Hazard ratios and 95% CIs for overall survival for year 1 comparing TNF inhibitors with conventional synthetic DMARDs in the three cohorts were 0·72 (0·43-1·21) for colorectal cancer, 0·70 (0·49-1·00) for lung cancer, and 0·80 (0·44-1·44) for prostate cancer. Patients who received glucocorticoids in the first year had significantly worse overall survival and cancer-specific survival than those who did not in the multivariable Cox proportional hazards models for the three cancers. INTERPRETATION: Treatment with TNF inhibitors during the first 3 years after diagnosis of colorectal, lung, or prostate cancer was not associated with poorer survival compared with those who received conventional synthetic DMARDs or those who did not receive any DMARDs. However, these findings might not be generalisable to other populations or types of cancer. FUNDING: National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases and NIH/National Cancer Institute through MD Andeson's Cancer Center Support Grant and Komen.
引用
- Ruiz JI, Lei X, Giordano SH, et al. Survival in patients with rheumatoid arthritis and recently diagnosed early-stage colorectal, lung, or prostate cancer receiving tumour necrosis factor inhibitors: a retrospective cohort study. Lancet Rheumatol. 2025. PMID: 39914441. doi:10.1016/S2665-9913(24)00379-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。